Sino Medical Sciences Technology (01302): The aortic arch stent system has obtained official registration approval from the China National Medical Products Administration.

Wisdom Financial News APP news, Sinocare Technology (01302) announced that on May 14, 2025, the aortic arch stent system ("the product") jointly developed by the National Cardiovascular Center, Professor Shuchang from Fuwai Hospital of the Chinese Academy of Medical Sciences, and this group has been officially registered and approved by the China National Medical Products Administration. This product is the first membrane stent system explicitly approved by the National Medical Products Administration for partial reconstruction of the aortic arch using fenestration technology. It is suitable for endovascular repair treatment of Stanford Type B aortic dissection patients, precisely maintaining perfusion of the left subclavian artery while repairing the aortic lesions, providing a finished instrument solution for patients with inadequate anchoring zones or involvement of the left subclavian artery.